Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study
Introduction The role of dapagliflozin on erectile dysfunction (ED), a condition widely affecting patients with type 2 diabetes mellitus (T2DM), has not yet been studied. Aim The aim of the study was to evaluate the effects of dapagliflozin alone or in combination with tadalafil on ED in patients wi...
Gespeichert in:
| Veröffentlicht in: | Diabetic medicine 2024-01, Vol.41 (1), p.e15217-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 1 |
| container_start_page | e15217 |
| container_title | Diabetic medicine |
| container_volume | 41 |
| creator | Cannarella, Rossella Condorelli, Rosita A. Leanza, Claudia Garofalo, Vincenzo Aversa, Antonio Papa, Giuseppe Calogero, Aldo E. La Vignera, Sandro |
| description | Introduction
The role of dapagliflozin on erectile dysfunction (ED), a condition widely affecting patients with type 2 diabetes mellitus (T2DM), has not yet been studied.
Aim
The aim of the study was to evaluate the effects of dapagliflozin alone or in combination with tadalafil on ED in patients with T2DM.
Methods
This was an open‐label, non‐randomized pilot study involving 30 Caucasian male patients with T2DM and severe ED. They were equally divided into three groups, assigned to treatment with tadalafil 5 mg/day (Group 1), tadalafil 5 mg/day plus dapagliflozin 10 mg/day (Group 2) and dapagliflozin 10 mg/day (Group 3) for 3 months. The presence and the severity of ED were evaluated at enrolment and after treatment, by the International Index of Erectile Function 5‐item (IIEF‐5) questionnaire and the dynamic penile echo colour Doppler ultrasound (PCDU) examination.
Results
At the end of treatment, the three groups showed a significant improvement in IIEF‐5 score, by 294%, 375% and 197%, in Groups 1, 2 and 3, respectively. PCDU evaluation showed a significant increase in peak systolic velocity by 178.9%, 339% and 153%; acceleration time was significantly shortened in Group 2 (−26.2%) and was significantly lower than in Group 1 and 3 (−7.2% and −6.6%), while no significant difference was found in end‐diastolic velocity after treatment. The greatest rates of improvement were observed in Group 2 for all the end points.
Conclusions
Dapagliflozin improves ED in patients with T2DM and enhances the efficacy of tadalafil. Further studies are needed to confirm our results explain the mechanism(s) by which dapagliflozin exerts its effects on ED. |
| doi_str_mv | 10.1111/dme.15217 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2861644184</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2901353932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-ba479b82b08cdbb5e9c6fecd4d8ce4369c56b8894f925b8c9b6620c6e376418e3</originalsourceid><addsrcrecordid>eNp1kctu1jAQhS0Eoj-FBS-ALLEBibTxJY7NrmrLRSpiA-vIlwm4cuwQO1TpigUPwDPyJLj8hQUSs_FY8_nojA9Cj0l7RGoduwmOSEdJfwftCBe86bgid9Gu7TltWNuTA_Qg58u2JVQxdR8dsF4IRRjZoe9netafgh9DuvYR-2le0lfIGBawxQfAbsvjGmuf6jTiWRcPsWR85ctnXLYZMMXOawOlvpogBF_W_BKfRJxmiD-__Qh1Fl7gmG4ui44uTf4aHJ59SAXnsrrtIbo36pDh0e15iD6-Ov9w-qa5eP_67enJRWOZlH1jNO-VkdS00jpjOlBWjGAdd9ICZ0LZThgpFR8V7Yy0yghBWyugrsuJBHaInu1165JfVshlmHy21bOOkNY8UCmI4BXlFX36D3qZ1iVWdwNVLWEdU4xW6vmeskvKeYFxmBc_6WUbSDvcRDPUaIbf0VT2ya3iaiZwf8k_WVTgeA9c1X_f_q80nL0730v-Av4Em-s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2901353932</pqid></control><display><type>article</type><title>Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Cannarella, Rossella ; Condorelli, Rosita A. ; Leanza, Claudia ; Garofalo, Vincenzo ; Aversa, Antonio ; Papa, Giuseppe ; Calogero, Aldo E. ; La Vignera, Sandro</creator><creatorcontrib>Cannarella, Rossella ; Condorelli, Rosita A. ; Leanza, Claudia ; Garofalo, Vincenzo ; Aversa, Antonio ; Papa, Giuseppe ; Calogero, Aldo E. ; La Vignera, Sandro</creatorcontrib><description>Introduction
The role of dapagliflozin on erectile dysfunction (ED), a condition widely affecting patients with type 2 diabetes mellitus (T2DM), has not yet been studied.
Aim
The aim of the study was to evaluate the effects of dapagliflozin alone or in combination with tadalafil on ED in patients with T2DM.
Methods
This was an open‐label, non‐randomized pilot study involving 30 Caucasian male patients with T2DM and severe ED. They were equally divided into three groups, assigned to treatment with tadalafil 5 mg/day (Group 1), tadalafil 5 mg/day plus dapagliflozin 10 mg/day (Group 2) and dapagliflozin 10 mg/day (Group 3) for 3 months. The presence and the severity of ED were evaluated at enrolment and after treatment, by the International Index of Erectile Function 5‐item (IIEF‐5) questionnaire and the dynamic penile echo colour Doppler ultrasound (PCDU) examination.
Results
At the end of treatment, the three groups showed a significant improvement in IIEF‐5 score, by 294%, 375% and 197%, in Groups 1, 2 and 3, respectively. PCDU evaluation showed a significant increase in peak systolic velocity by 178.9%, 339% and 153%; acceleration time was significantly shortened in Group 2 (−26.2%) and was significantly lower than in Group 1 and 3 (−7.2% and −6.6%), while no significant difference was found in end‐diastolic velocity after treatment. The greatest rates of improvement were observed in Group 2 for all the end points.
Conclusions
Dapagliflozin improves ED in patients with T2DM and enhances the efficacy of tadalafil. Further studies are needed to confirm our results explain the mechanism(s) by which dapagliflozin exerts its effects on ED.</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.15217</identifier><identifier>PMID: 37669131</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antidiabetics ; Carbolines ; dapagliflozin ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Doppler effect ; Erectile dysfunction ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - etiology ; Humans ; Male ; Penis ; Pilot Projects ; SGLT2i ; T2DM ; tadalafil ; Tadalafil - therapeutic use ; Treatment Outcome ; Velocity</subject><ispartof>Diabetic medicine, 2024-01, Vol.41 (1), p.e15217-n/a</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd on behalf of Diabetes UK.</rights><rights>2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-ba479b82b08cdbb5e9c6fecd4d8ce4369c56b8894f925b8c9b6620c6e376418e3</citedby><cites>FETCH-LOGICAL-c3887-ba479b82b08cdbb5e9c6fecd4d8ce4369c56b8894f925b8c9b6620c6e376418e3</cites><orcidid>0000-0003-4599-8487</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdme.15217$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdme.15217$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37669131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cannarella, Rossella</creatorcontrib><creatorcontrib>Condorelli, Rosita A.</creatorcontrib><creatorcontrib>Leanza, Claudia</creatorcontrib><creatorcontrib>Garofalo, Vincenzo</creatorcontrib><creatorcontrib>Aversa, Antonio</creatorcontrib><creatorcontrib>Papa, Giuseppe</creatorcontrib><creatorcontrib>Calogero, Aldo E.</creatorcontrib><creatorcontrib>La Vignera, Sandro</creatorcontrib><title>Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study</title><title>Diabetic medicine</title><addtitle>Diabet Med</addtitle><description>Introduction
The role of dapagliflozin on erectile dysfunction (ED), a condition widely affecting patients with type 2 diabetes mellitus (T2DM), has not yet been studied.
Aim
The aim of the study was to evaluate the effects of dapagliflozin alone or in combination with tadalafil on ED in patients with T2DM.
Methods
This was an open‐label, non‐randomized pilot study involving 30 Caucasian male patients with T2DM and severe ED. They were equally divided into three groups, assigned to treatment with tadalafil 5 mg/day (Group 1), tadalafil 5 mg/day plus dapagliflozin 10 mg/day (Group 2) and dapagliflozin 10 mg/day (Group 3) for 3 months. The presence and the severity of ED were evaluated at enrolment and after treatment, by the International Index of Erectile Function 5‐item (IIEF‐5) questionnaire and the dynamic penile echo colour Doppler ultrasound (PCDU) examination.
Results
At the end of treatment, the three groups showed a significant improvement in IIEF‐5 score, by 294%, 375% and 197%, in Groups 1, 2 and 3, respectively. PCDU evaluation showed a significant increase in peak systolic velocity by 178.9%, 339% and 153%; acceleration time was significantly shortened in Group 2 (−26.2%) and was significantly lower than in Group 1 and 3 (−7.2% and −6.6%), while no significant difference was found in end‐diastolic velocity after treatment. The greatest rates of improvement were observed in Group 2 for all the end points.
Conclusions
Dapagliflozin improves ED in patients with T2DM and enhances the efficacy of tadalafil. Further studies are needed to confirm our results explain the mechanism(s) by which dapagliflozin exerts its effects on ED.</description><subject>Antidiabetics</subject><subject>Carbolines</subject><subject>dapagliflozin</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Doppler effect</subject><subject>Erectile dysfunction</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Penis</subject><subject>Pilot Projects</subject><subject>SGLT2i</subject><subject>T2DM</subject><subject>tadalafil</subject><subject>Tadalafil - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Velocity</subject><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctu1jAQhS0Eoj-FBS-ALLEBibTxJY7NrmrLRSpiA-vIlwm4cuwQO1TpigUPwDPyJLj8hQUSs_FY8_nojA9Cj0l7RGoduwmOSEdJfwftCBe86bgid9Gu7TltWNuTA_Qg58u2JVQxdR8dsF4IRRjZoe9netafgh9DuvYR-2le0lfIGBawxQfAbsvjGmuf6jTiWRcPsWR85ctnXLYZMMXOawOlvpogBF_W_BKfRJxmiD-__Qh1Fl7gmG4ui44uTf4aHJ59SAXnsrrtIbo36pDh0e15iD6-Ov9w-qa5eP_67enJRWOZlH1jNO-VkdS00jpjOlBWjGAdd9ICZ0LZThgpFR8V7Yy0yghBWyugrsuJBHaInu1165JfVshlmHy21bOOkNY8UCmI4BXlFX36D3qZ1iVWdwNVLWEdU4xW6vmeskvKeYFxmBc_6WUbSDvcRDPUaIbf0VT2ya3iaiZwf8k_WVTgeA9c1X_f_q80nL0730v-Av4Em-s</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Cannarella, Rossella</creator><creator>Condorelli, Rosita A.</creator><creator>Leanza, Claudia</creator><creator>Garofalo, Vincenzo</creator><creator>Aversa, Antonio</creator><creator>Papa, Giuseppe</creator><creator>Calogero, Aldo E.</creator><creator>La Vignera, Sandro</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4599-8487</orcidid></search><sort><creationdate>202401</creationdate><title>Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study</title><author>Cannarella, Rossella ; Condorelli, Rosita A. ; Leanza, Claudia ; Garofalo, Vincenzo ; Aversa, Antonio ; Papa, Giuseppe ; Calogero, Aldo E. ; La Vignera, Sandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-ba479b82b08cdbb5e9c6fecd4d8ce4369c56b8894f925b8c9b6620c6e376418e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antidiabetics</topic><topic>Carbolines</topic><topic>dapagliflozin</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Doppler effect</topic><topic>Erectile dysfunction</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Penis</topic><topic>Pilot Projects</topic><topic>SGLT2i</topic><topic>T2DM</topic><topic>tadalafil</topic><topic>Tadalafil - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Velocity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cannarella, Rossella</creatorcontrib><creatorcontrib>Condorelli, Rosita A.</creatorcontrib><creatorcontrib>Leanza, Claudia</creatorcontrib><creatorcontrib>Garofalo, Vincenzo</creatorcontrib><creatorcontrib>Aversa, Antonio</creatorcontrib><creatorcontrib>Papa, Giuseppe</creatorcontrib><creatorcontrib>Calogero, Aldo E.</creatorcontrib><creatorcontrib>La Vignera, Sandro</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cannarella, Rossella</au><au>Condorelli, Rosita A.</au><au>Leanza, Claudia</au><au>Garofalo, Vincenzo</au><au>Aversa, Antonio</au><au>Papa, Giuseppe</au><au>Calogero, Aldo E.</au><au>La Vignera, Sandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study</atitle><jtitle>Diabetic medicine</jtitle><addtitle>Diabet Med</addtitle><date>2024-01</date><risdate>2024</risdate><volume>41</volume><issue>1</issue><spage>e15217</spage><epage>n/a</epage><pages>e15217-n/a</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><abstract>Introduction
The role of dapagliflozin on erectile dysfunction (ED), a condition widely affecting patients with type 2 diabetes mellitus (T2DM), has not yet been studied.
Aim
The aim of the study was to evaluate the effects of dapagliflozin alone or in combination with tadalafil on ED in patients with T2DM.
Methods
This was an open‐label, non‐randomized pilot study involving 30 Caucasian male patients with T2DM and severe ED. They were equally divided into three groups, assigned to treatment with tadalafil 5 mg/day (Group 1), tadalafil 5 mg/day plus dapagliflozin 10 mg/day (Group 2) and dapagliflozin 10 mg/day (Group 3) for 3 months. The presence and the severity of ED were evaluated at enrolment and after treatment, by the International Index of Erectile Function 5‐item (IIEF‐5) questionnaire and the dynamic penile echo colour Doppler ultrasound (PCDU) examination.
Results
At the end of treatment, the three groups showed a significant improvement in IIEF‐5 score, by 294%, 375% and 197%, in Groups 1, 2 and 3, respectively. PCDU evaluation showed a significant increase in peak systolic velocity by 178.9%, 339% and 153%; acceleration time was significantly shortened in Group 2 (−26.2%) and was significantly lower than in Group 1 and 3 (−7.2% and −6.6%), while no significant difference was found in end‐diastolic velocity after treatment. The greatest rates of improvement were observed in Group 2 for all the end points.
Conclusions
Dapagliflozin improves ED in patients with T2DM and enhances the efficacy of tadalafil. Further studies are needed to confirm our results explain the mechanism(s) by which dapagliflozin exerts its effects on ED.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37669131</pmid><doi>10.1111/dme.15217</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-4599-8487</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0742-3071 |
| ispartof | Diabetic medicine, 2024-01, Vol.41 (1), p.e15217-n/a |
| issn | 0742-3071 1464-5491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2861644184 |
| source | MEDLINE; Wiley Journals |
| subjects | Antidiabetics Carbolines dapagliflozin Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Doppler effect Erectile dysfunction Erectile Dysfunction - drug therapy Erectile Dysfunction - etiology Humans Male Penis Pilot Projects SGLT2i T2DM tadalafil Tadalafil - therapeutic use Treatment Outcome Velocity |
| title | Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T09%3A03%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dapagliflozin%20improves%20erectile%20dysfunction%20in%20patients%20with%20type%202%20diabetes%20mellitus:%20An%20open%E2%80%90label,%20non%E2%80%90randomized%20pilot%20study&rft.jtitle=Diabetic%20medicine&rft.au=Cannarella,%20Rossella&rft.date=2024-01&rft.volume=41&rft.issue=1&rft.spage=e15217&rft.epage=n/a&rft.pages=e15217-n/a&rft.issn=0742-3071&rft.eissn=1464-5491&rft_id=info:doi/10.1111/dme.15217&rft_dat=%3Cproquest_cross%3E2901353932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2901353932&rft_id=info:pmid/37669131&rfr_iscdi=true |